7.65
price down icon21.20%   -2.0576
after-market Dopo l'orario di chiusura: 8.22 0.57 +7.45%
loading
Precedente Chiudi:
$9.7076
Aprire:
$8.25
Volume 24 ore:
175.79K
Relative Volume:
0.58
Capitalizzazione di mercato:
$8.29M
Reddito:
-
Utile/perdita netta:
$-14.93M
Rapporto P/E:
-0.0287
EPS:
-266.137
Flusso di cassa netto:
$-15.87M
1 W Prestazione:
-21.98%
1M Prestazione:
-31.35%
6M Prestazione:
-97.56%
1 anno Prestazione:
-98.97%
Intervallo 1D:
Value
$7.19
$8.9869
Intervallo di 1 settimana:
Value
$7.19
$10.36
Portata 52W:
Value
$6.1478
$1,838.76

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Name
Nome
Transcode Therapeutics Inc
Name
Telefono
857-301-6857
Name
Indirizzo
6 LIBERTY SQUARE, BOSTON
Name
Dipendente
7
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
RNAZ's Discussions on Twitter

Confronta RNAZ con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RNAZ
Transcode Therapeutics Inc
7.65 8.29M 0 -14.93M -15.87M -266.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.38 111.66B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
584.99 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
561.75 38.04B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
283.40 36.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
225.77 25.10B 3.81B -644.79M -669.77M -6.24

Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie

pulisher
May 14, 2025

Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus

May 14, 2025
pulisher
May 14, 2025

TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World

May 14, 2025
pulisher
May 09, 2025

(RNAZ) Investment Report - news.stocktradersdaily.com

May 09, 2025
pulisher
May 08, 2025

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan

May 08, 2025
pulisher
May 07, 2025

TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks

May 07, 2025
pulisher
May 05, 2025

TransCode Therapeutics Announces Reverse Stock Split - TipRanks

May 05, 2025
pulisher
May 05, 2025

TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan

May 05, 2025
pulisher
May 05, 2025

US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga

May 05, 2025
pulisher
May 05, 2025

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PR Newswire

May 05, 2025
pulisher
May 05, 2025

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga

May 05, 2025
pulisher
May 04, 2025

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz

May 04, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Offerings News Live Feed - Stock Titan

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com South Africa

May 02, 2025
pulisher
May 02, 2025

Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan

May 02, 2025
pulisher
May 02, 2025

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN

May 02, 2025
pulisher
May 02, 2025

For Dropbox Inc [DBX], Analyst sees a drop to $30. What next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Direct Digital Holdings Inc [DRCT] is -44.37% lower this YTD. Is it still time to buy? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

CN Energy Group Inc [CNEY] Is Currently 9.75 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Wall Street Analyst Upgrade Rush Street Interactive Inc [RSI]. What else is Wall St. saying - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Glaukos Corporation [GKOS] Revenue clocked in at $383.48 million, down -44.28% YTD: What’s Next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Republic Digital Acquisition Company [RDAGU] Stock trading around $10.15 per share: What’s Next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Venture Global Inc [VG] stock Initiated by UBS analyst, price target now $14 - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Hayward Holdings Inc [HAYW] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Market cap of Solaris Energy Infrastructure Inc [SEI] reaches 1.55B – now what? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

why Astera Labs Inc [ALAB] is a Good Choice for Investors After New Price Target of $111.21 - dbtnews.com

May 02, 2025
pulisher
May 01, 2025

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - The Globe and Mail

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (RNAZ) Advances Clinical Trial of TTX-MC1 - GuruFocus

May 01, 2025
pulisher
May 01, 2025

TransCode's Cancer Drug Achieves Major Safety Milestone: 13 Patients Show No Toxicity in Latest Trial Data - Stock Titan

May 01, 2025
pulisher
May 01, 2025

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Selling Your TransCode Therapeutics Inc (NASDAQ: RNAZ) Stock? Here’s What You Need To Know - Stocksregister

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (RNAZ) Adjourns Special Meeting to May 2 - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

TransCode Therapeutics Inc (RNAZ) can make a big difference with a little luck - Sete News

Apr 30, 2025
pulisher
Apr 30, 2025

Does Arbe Robotics Ltd (ARBE) offer a good opportunity for investors? - Sete News

Apr 30, 2025
pulisher
Apr 30, 2025

A Look at Murphy Oil Corp (MUR) Shares in the Recent Past Indicates Growth - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

TransCode Therapeutics Inc (RNAZ) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com

Apr 29, 2025
pulisher
Apr 28, 2025

TransCode Therapeutics stock slides after announces to raise $10M securities offering - MSN

Apr 28, 2025
pulisher
Apr 28, 2025

TransCode Therapeutics Inc (RNAZ) deserves closer scrutiny - uspostnews.com

Apr 28, 2025
pulisher
Apr 28, 2025

Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreases By 59.2% - Defense World

Apr 28, 2025
pulisher
Apr 23, 2025

(RNAZ) Trading Signals - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 22, 2025

What’s The Deal With TransCode Therapeutics Inc (NASDAQ: RNAZ)? - Stocksregister

Apr 22, 2025
pulisher
Apr 21, 2025

TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum - Stock Titan

Apr 21, 2025

Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.22
price up icon 2.45%
$19.65
price up icon 2.99%
$33.12
price up icon 2.57%
$23.09
price up icon 1.49%
$92.34
price up icon 0.28%
biotechnology ONC
$225.77
price up icon 2.65%
Capitalizzazione:     |  Volume (24 ore):